BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31715074)

  • 1. Label-Free Quantitative Proteomics Identifies Novel Biomarkers for Distinguishing Tuberculosis Pleural Effusion from Malignant Pleural Effusion.
    Pan L; Zhang X; Jia H; Huang M; Liu F; Wang J; Du B; Wei R; Sun Q; Xing A; Li Q; Zhang Z
    Proteomics Clin Appl; 2020 Jan; 14(1):e1900001. PubMed ID: 31715074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic pilot study of tuberculosis pleural effusion.
    Zhang J; Fang LZ; Liu L; Zhang J; Fu W; Dai L
    Biomed Mater Eng; 2015; 26 Suppl 1():S2223-32. PubMed ID: 26406002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of differentially expressed miRNAs in differentiating benign from malignant pleural effusion.
    Bao Q; Xu Y; Ding M; Chen P
    Hereditas; 2020 Feb; 157(1):6. PubMed ID: 32102688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Value of Vascular Endothelial Growth Factor, Transforming Growth Factor-β, Interleukin-8, and the Ratio of Lactate Dehydrogenase to Adenosine Deaminase in Pleural Effusion.
    Saraya T; Ohkuma K; Watanabe T; Mikura S; Kobayashi F; Aso J; Nunokawa H; Honda K; Ogawa Y; Tamura M; Sada M; Oda M; Inoue M; Yokoyama T; Kurai D; Ishii H; Kimura H; Takizawa H
    Lung; 2018 Apr; 196(2):249-254. PubMed ID: 29353318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas.
    Sriram KB; Relan V; Clarke BE; Duhig EE; Windsor MN; Matar KS; Naidoo R; Passmore L; McCaul E; Courtney D; Yang IA; Bowman RV; Fong KM
    BMC Cancer; 2012 Sep; 12():428. PubMed ID: 23009708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-free DNA methylation analysis as a marker of malignancy in pleural fluid.
    Bixby B; Vrba L; Lenka J; Oshiro MM; Watts GS; Hughes T; Erickson H; Chopra M; Knepler JL; Knox KS; Jarnagin L; Alalawi R; Kala M; Bernert R; Routh J; Roe DJ; Garland LL; Futscher BW; Nelson MA
    Sci Rep; 2024 Feb; 14(1):2939. PubMed ID: 38316884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of a panel of miRNAs in serum and pleural fluid for the differential diagnosis of malignant and benign pleural effusion.
    Zhu LR; Yuan RX; Xia XB; Wang Y; Zhu YM; Fi L; Li J
    Cancer Biomark; 2022; 33(1):71-82. PubMed ID: 34366325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleural IFN-γ release assay combined with biomarkers distinguished effectively tuberculosis from malignant pleural effusion.
    Tang Y; Zhang J; Huang H; He X; Zhang J; Ou M; Li G; Zeng C; Ye T; Ren L; Liu Y; Zhang G
    BMC Infect Dis; 2019 Jan; 19(1):55. PubMed ID: 30651075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GC-MS metabolomics identifies novel biomarkers to distinguish tuberculosis pleural effusion from malignant pleural effusion.
    Liu Y; Mei B; Chen D; Cai L
    J Clin Lab Anal; 2021 Apr; 35(4):e23706. PubMed ID: 33528039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion].
    Wei F; Wei Y; Li LF; Li GL; Wang GJ
    Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):524-527. PubMed ID: 28728299
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantitative proteomics revealed protein biomarkers to distinguish malignant pleural effusion from benign pleural effusion.
    Dong T; Liang Y; Chen H; Li Y; Li Z; Gao X
    J Proteomics; 2024 May; 302():105201. PubMed ID: 38768894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a machine learning model for differential diagnosis of malignant pleural effusion using routine laboratory data.
    Wei TT; Zhang JF; Cheng Z; Jiang L; Li JY; Zhou L
    Ther Adv Respir Dis; 2023; 17():17534666231208632. PubMed ID: 37941347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidine kinase 1 concentration in pleural effusion is a diagnostic marker and survival predictor for malignant pleural effusion.
    Tian T; Li J; Hu W; Sun C; Zhou J
    J Clin Lab Anal; 2019 Jul; 33(6):e22901. PubMed ID: 30985967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel diagnostic method for distinguishing parapneumonic effusion and empyema from other diseases by using the pleural lactate dehydrogenase to adenosine deaminase ratio and carcinoembryonic antigen levels.
    Saraya T; Ohkuma K; Koide T; Goto H; Takizawa H; Light RW
    Medicine (Baltimore); 2019 Mar; 98(13):e15003. PubMed ID: 30921217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of 10 Candidate Biomarkers Distinguishing Tuberculous and Malignant Pleural Fluid by Proteomic Methods.
    Lee CY; Hong JY; Lee MG; Suh IB
    Yonsei Med J; 2017 Nov; 58(6):1144-1151. PubMed ID: 29047238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion.
    Dong J; Sun G; Zhu H
    Tumour Biol; 2016 Mar; 37(3):3257-64. PubMed ID: 26438059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Platelet Parameters in the Differential Diagnosis of Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Tuberculous Pleural Effusion.
    Ai L; Li J; Ye T; Wang W; Li Y
    Dis Markers; 2022; 2022():5653033. PubMed ID: 35531478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion.
    Han HS; Yun J; Lim SN; Han JH; Lee KH; Kim ST; Kang MH; Son SM; Lee YM; Choi SY; Yun SJ; Kim WJ; Lee OJ
    Int J Cancer; 2013 Aug; 133(3):645-52. PubMed ID: 23354517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity of procalcitonin and C-reactive protein measurement when differentiating between benign and malignant pleural effusion.
    Botana-Rial M; Casado-Rey P; Leiro-Fernández V; Andrade-Olivié M; Represas-Represas C; Fernández-Villar A
    Clin Lab; 2011; 57(5-6):373-8. PubMed ID: 21755828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-depth proteomic analysis of six types of exudative pleural effusions for nonsmall cell lung cancer biomarker discovery.
    Liu PJ; Chen CD; Wang CL; Wu YC; Hsu CW; Lee CW; Huang LH; Yu JS; Chang YS; Wu CC; Yu CJ
    Mol Cell Proteomics; 2015 Apr; 14(4):917-32. PubMed ID: 25638566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.